Risk of 3‐Year Cytological Progression by Baseline HPV Status Among Women With Normal Cytology: A Multicenter Cohort Study
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71855 ↗At a glance
Multizentrische Studie in Cancer Medicine, published online on 2026-04-21. Written by Chong-Bi Huang and 17 co-authors. Institution: Department of Epidemiology and Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. Major MEDLINE topics: Human Papillomavirus Viruses, Papillomaviridae, Papillomavirus Infections, Uterine Cervical Dysplasia. 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China, Yunnan Fundamental Research Projects.
Abstract (original language)
Tailored cervical cancer screening strategies are essential, particularly in resource‐limited settings. This study aimed to assess the genotype‐specific impact of high‐risk human papillomavirus (HR‐HPV) infections on cervical cytological progression over a 3‐year interval among Chinese women, thereby providing evidence for more precise and individualized screening approaches. A multicenter cohort was established in 2017 across three Chinese provinces. Participants underwent baseline HPV genotyping and cytological examination, with genotyping for five high‐risk types (HPV16, 18, 33, 52, and 58), and follow‐up evaluations conducted from 2018 to 2020. Cytological progression was defined as a transition from normal cytology (negative for intraepithelial lesion or malignancy, NILM) at baseline to low‐grade squamous intraepithelial lesion (LSIL) or worse at the final follow‐up. A total of 7240 women were included to evaluate the cytological progression. The overall progression rate was 0.7%, with a notably higher rate among HR‐HPV‐positive women (2.1%) compared to HR‐HPV‐negative women (0.5%). Specifically, HPV16, HPV52, and HPV58 were significantly associated with an increased risk of progression, with adjusted odds ratios (aORs) of 6.26 (95% CI: 2.62–14.95), 6.68 (95% CI: 3.30–13.53), and 4.24 (95% CI: 1.51–11.94), respectively. Moreover, women with persistent infections with HPV16, HPV52, and HPV58 had approximately 8‐fold, 6‐fold, and 5‐fold higher risks of progression, respectively, compared with women without infections. Stratified management based on high‐risk genotypes—particularly HPV16, HPV52, and HPV58—may help prioritize colposcopy and more intensive follow‐up for women at elevated risk, which could contribute to cervical cancer prevention efforts. Trial Registration: Chinese Clinical Trial Registry Center of the World Health Organization International Clinical Trials Registry Platform number: ChiCRT2200055287
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Epidemiology and Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
- Department of Gynecology and Obstetrics, West China Second University Hospital & Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
- Department of Cancer Epidemiology and Prevention, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, The Affiliated Cancer Hospital of Zhengzho…
- Department of Public Health and Preventive Medicine, Changzhi Medical College, Changzhi, China.
- National Office for Maternal and Child Health Surveillance, West China Second University Hospital, Sichuan University, Chengdu, China.
- Department of Global Health, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID profiles: Chong-Bi Huang, Fan Zhao, You-Lin Qiao, Wen Chen, Yin Liu
Funding
- National Natural Science Foundation of China
- Yunnan Fundamental Research Projects
Cite
APA
Huang, C. B., Liao, G. D., Zhang, S. K., Zeng, X., Li, Z. F., Zhao, D. D., Zhao, F., Ao, M. Y., Kang, L. N., Qiao, Y. L., Chen, W., Liu, Y., Xu, L., Yuan, M. W., Xue, S. L., Liu, S. Y., Xi, M. R., & Li, J. (2026). Risk of 3‐Year Cytological Progression by Baseline HPV Status Among Women With Normal Cytology: A Multicenter Cohort Study. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71855
Vancouver
Huang CB, Liao GD, Zhang SK, Zeng X, Li ZF, Zhao DD, et al. Risk of 3‐Year Cytological Progression by Baseline HPV Status Among Women With Normal Cytology: A Multicenter Cohort Study. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71855
BibTeX
@article{Huang2026,
author = {Huang, Chong-Bi and Liao, Guang-Dong and Zhang, Shao-Kai and Zeng, Xi and Li, Zhi-Fang and Zhao, Dan-Dan and Zhao, Fan and Ao, Meng-Yin and Kang, Le-Ni and Qiao, You-Lin and Chen, Wen and Liu, Yin and Xu, Lian and Yuan, Ming-Wei and Xue, Shao-Long and Liu, Shu-Yuan and Xi, Ming-Rong and Li, Jing},
title = {Risk of 3‐Year Cytological Progression by Baseline HPV Status Among Women With Normal Cytology: A Multicenter Cohort Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71855}
}
EUVIMED